{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:04:20Z","timestamp":1787162660745,"version":"build-2736575974"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T00:00:00Z","timestamp":1630368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Cardiology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Some randomized controlled trials have compared the effectiveness and safety outcomes between early initiation of Sacubitril\/Valsartan and angiotensin\u2010converting enzyme inhibitors (ACEIs) in patients after acute myocardial infarction. Therefore, our current meta\u2010analysis aimed to clarify the confusion. Four Databases and relevant grey literature were searched for studies from inception to July 2, 2021. Two reviewers independently screened literature, extracted data, and assessed the risk of bias. Four studies involving 6154 patients were included to perform meta\u2010analysis. The results of meta\u2010analysis showed that the left ventricular ejection fraction in the Sacubitril\/Valsartan group was higher than the ACEI group (SMD: 0.37, 95% CI: 0.19\u20130.55,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.000), the incidence of major adverse cardiac events in the Sacubitril\/Valsartan group was lower than the ACEI group (RR: 0.61, 95% CI: 0.46\u20130.82,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.001), while the incidences of cardiac death (RR: 1.00, 95% CI: 0.81\u20131.24,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a01.000) and the heart failure hospitalization (RR: 0.62, 95% CI: 0.37\u20131.03,\n                    <jats:italic>P<\/jats:italic>\n                    \u00a0=\u00a0.065) showed no difference. For the incidences of myocardial infarction and the adverse side effects, there was no obvious advantage of the Sacubitril\/Valsartan group over the ACEI group, because the meta\u2010analysis was not performed due to the limited trials. This study indicated that early initiation of Sacubitril\/Valsartan in patients after acute myocardial infarction was superior to ACEI in reducing the risks of major adverse cardiac events and left ventricular ejection fraction increasing. As for the other outcomes (the incidences of cardiac death, the heart failure hospitalization, the myocardial infarction and the adverse side effects), Sacubitril\/Valsartan showed no obvious advantage than ACEI.\n                  <\/jats:p>","DOI":"10.1002\/clc.23717","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T14:18:51Z","timestamp":1630419531000},"page":"1354-1359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of early initiation of Sacubitril\/Valsartan in patients after acute myocardial infarction: A meta\u2010analysis"],"prefix":"10.1002","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7346-9959","authenticated-orcid":false,"given":"Jing","family":"Zhao","sequence":"first","affiliation":[{"name":"Cardiology Department Dongzhimen Hospital, Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Cardiology Department Dongzhimen Hospital, Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxu","family":"Shen","sequence":"additional","affiliation":[{"name":"Cardiology Department Dongzhimen Hospital, Beijing University of Chinese Medicine  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,8,31]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300268"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.115.002460"},{"issue":"10","key":"e_1_2_9_4_1","first-page":"760","article-title":"2018 Chinese guidelines for the diagnosis and trearment of heart failure","volume":"46","author":"Wang H","year":"2018","journal-title":"Chin J Cardiol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.97.22.2202"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.592"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.05.019"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.04.025"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851"},{"key":"e_1_2_9_11_1","volume-title":"A prospective, randomized, controlled trial for the efficacy and safety of improving left ventricular remodeling in combined use of sacubitril\u2010valsartan and dapagliflozin compared to RAAS inhibitors in very elderly patients with acute myocardial infarction at the early stage of hospitalization","author":"ChiCtr","year":"2020"},{"key":"e_1_2_9_12_1","volume-title":"Studying the effect of medication (sacubitril\/valsartan) on heart muscle damage after heart attacks","author":"Euctr GB","year":"2018"},{"key":"e_1_2_9_13_1","volume-title":"Early Treatment of ARNI on Myocardial Remodeling and Progress","author":"Nct","year":"2018"},{"key":"e_1_2_9_14_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)","author":"Higgins J","year":"2021"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2020.12.037"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000932"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0000000000000955"},{"key":"e_1_2_9_18_1","volume-title":"Prospective ARNI vs. ACE inhibitor trial to DetermIne Superiority in reducing heart failure Events after Myocardial Infarction","author":"Kumbhani DJ","year":"2021"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3904\/kjim.2020.105"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12694"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.121.054892"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2191"},{"key":"e_1_2_9_23_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions (version 6.2)","author":"Higgins J","year":"2021"}],"container-title":["Clinical Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23717","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/clc.23717","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/clc.23717","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T19:36:40Z","timestamp":1693337800000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/clc.23717"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,31]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1002\/clc.23717"],"URL":"https:\/\/doi.org\/10.1002\/clc.23717","archive":["Portico"],"relation":{},"ISSN":["0160-9289","1932-8737"],"issn-type":[{"value":"0160-9289","type":"print"},{"value":"1932-8737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,31]]},"assertion":[{"value":"2021-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}